← ANALYSTS · TIPRANKS
Kaveri Pohlman · Clear Street
Hits
40%
92 of 229 ratings made money (TipRanks, all the analyst’s ratings)
Average return of a rating
+12.9%
Over a year after the rating, TipRanks’ measure
Our companies rated now
20
Buy / hold / sell: 19 / 1 / 0
Upside of the analyst’s targets
+211.2%
Average over 20 current targets, to the last price
The market’s answer to the ratings
+2.8%
Day-0 move against SPY in the rating’s direction, average over 13 upgrades, downgrades and target changes
| Date · added, NY | Stock | Action | Rating | Price target | Upside | Move vs SPY | |
|---|---|---|---|---|---|---|---|
| Oct 6on TipRanks Oct 7 04:06 | AVBPIWMArriVent BioPharma, Inc. · $828M | Reiterated | Buy | $47.00 → $22.00−53.2% | +32.1% | −47.5%next day +12.2% · 5 days +6.8% | ↗ |
| Sep 30on TipRanks 17:55 | SGMTIWMSagimet Biosciences, Inc. Class A · $575M | Reiterated | Buy | $28.00 | +249.1% | −5.3%next day −3.2% · 5 days −6.1% | ↗ |
| Sep 29on TipRanks Sep 28 16:45 | QTTBQ32 Bio · $246M | Initiated | Buy | $38.00 | +405.3% | +3.4%next day −13.0% · 5 days −16.8% | ↗ |
| Sep 23on TipRanks 09:35 | ORKAIWMOruka Therapeutics · $4.9B | Reiterated | Buy | $131 | +82.1% | −4.2%next day −4.8% · 5 days −6.7% | ↗ |
| Sep 9on TipRanks 19:55 | EVMNIWMEvommune, Inc. · $215M | Reiterated | Buy | $28.00 → $23.00−17.9% | +344.9% | −2.0%next day −1.0% · 5 days −11.9% | ↗ |
| Sep 4on TipRanks Sep 3 16:30 | JBIOIWMJade Biosciences · $855M | Assigned | Buy | $25.00 → $48.00+92.0% | +256.3% | +0.6%next day −1.7% · 5 days −7.4% | ↗ |
| Aug 31on TipRanks 20:30 | PTGXIWMProtagonist Therapeutics · $8.8B | Reiterated | Buy | $173 | +34.4% | −0.2%next day −0.7% · 5 days −1.0% | ↗ |
| Aug 21on TipRanks Aug 20 16:20 | LBRXIWMLB Pharmaceuticals, Inc. · $1.2B | Assigned | Buy | $45.00 → $69.00+53.3% | +87.8% | +0.4%next day +1.5% · 5 days −0.2% | ↗ |
| Aug 14on TipRanks Aug 13 09:30 | CGEMIWMCullinan Management · $901M | Assigned | Buy | $46.00 → $47.00+2.2% | +263.5% | −0.5%next day +3.8% · 5 days +10.8% | ↗ |
| Aug 6on TipRanks 06:15 | ELVNIWMEnliven Therapeutics · $2.9B | Assigned | Buy | $55.00 → $68.00+23.6% | +82.2% | +1.1%next day −0.3% · 5 days −4.9% | ↗ |
| Jun 22on TipRanks 13:50 | MLTXMoonLake Immunotherapeutics · $873M | Reiterated | Buy | $70.00 | +633.0% | +15.7%next day −2.8% · 5 days −9.7% | ↗ |
| May 7on TipRanks 18:00 | TRVIIWMTrevi Therapeutics · $1.7B | Reiterated | Buy | $21.00 → $29.00+38.1% | +144.1% | +2.4%next day +2.4% · 5 days −2.3% | ↗ |
| May 6on TipRanks 17:05 | MDGLMadrigal Pharmaceuticals · $10.4B | Reiterated | Buy | $533 → $680+27.6% | +51.2% | −0.6%next day −5.5% · 5 days −1.3% | ↗ |
| Mar 31on TipRanks Apr 1 08:40 | PALIIWMPalisade Bio · $268M | Reiterated | Buy | $12.00 | +751.1% | −4.6%next day +6.7% · 5 days +2.9% | ↗ |
| Mar 6on TipRanks Mar 5 17:25 | ERASIWMErasca · $5.2B | Assigned | Buy | $11.00 → $20.00+81.8% | +49.4% | +0.9%next day +1.0% · 5 days −10.5% | ↗ |
| Mar 2on TipRanks Mar 1 17:30 | PVLAIWMPalvella Therapeutics · $1.8B | Reiterated | Buy | $200 → $220+10.0% | +82.9% | −1.8%next day +0.1% · 5 days +4.3% | ↗ |
| Jan 20on TipRanks 05:25 | JANXIWMJanux Therapeutics Inc · $1.1B | Downgrade | Hold | $32.00 → $12.00−62.5% | −27.3% | −2.4%next day −0.2% · 5 days +9.4% | ↗ |
| Dec 11on TipRanks 13:10 | IMTXImmatics · $1.1B | Reiterated | Buy | $18.00 | +167.5% | −0.4%next day +1.1% · 5 days −2.8% | ↗ |
| Dec 1on TipRanks Dec 2 09:10 | ZURAIWMZura Bio · $423M | Reiterated | Buy | $18.00 | +363.9% | −2.7%next day −5.8% · 5 days +0.9% | ↗ |
| Nov 26on TipRanks 14:05 | NUVBIWMNuvation Bio · $1.7B | Reiterated | Buy | $12.00 | +169.7% | +1.0%next day −0.3% · 5 days +3.1% | ↗ |
| Nov 11on TipRanks Nov 10 08:35 | AVBPIWMArriVent BioPharma, Inc. · $828M | Reiterated | Buy | $32.00 → $47.00+46.9% | +182.1% | +1.5%next day +4.0% · 5 days +13.6% | ↗ |
| No ratings for this filter. | |||||||
Ratings of the stocks the collector reads (the companies of QQQ, SPY, IWM, SMH, SOXL and SOXS and the other US stocks of TipRanks’ feed of new ratings) that it has kept: every new one since 30 September 2026, before that the analyst’s latest rating of each company. Upside is the target over the stock’s last price. The analyst at TipRanks ↗